Memo Therapeutics AG
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability and Efficacy of AntiBKV As Treatment of BKV Infection in Kidney Transplant Recipients
- Conditions
- BK Viremia; BKV DNAemia
- Interventions
- Biological: Anti-BK polyomavirus (AntiBKV)
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Memo Therapeutics AG
- Target Recruit Count
- 180
- Registration Number
- NCT05769582
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.
- Conditions
- BK Virus Nephropathy
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Memo Therapeutics AG
- Target Recruit Count
- 40
- Registration Number
- NCT05358106
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Memo Therapeutics AG
- Target Recruit Count
- 32
- Registration Number
- NCT05351437
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
News
Memo Therapeutics to Present Phase II Results for First-in-Class BK Polyomavirus Treatment at World Transplant Congress
Memo Therapeutics will present interim Phase II results for potravitug, a monoclonal antibody targeting BK polyomavirus infection in kidney transplant recipients, at the World Transplant Congress in August 2025.
Memo Therapeutics Demonstrates Therapeutic Antibodies Can Cross Kidney Barrier, Supporting BK Virus Treatment Approach
Memo Therapeutics published research in Frontiers in Pharmacology showing that intravenously administered therapeutic IgG antibodies can cross the kidney endothelial barrier and be detected in urine.
Memo Therapeutics AG Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for BK viremia in kidney transplant patients.
Memo Therapeutics Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for BK viremia in kidney transplant patients.
Memo Therapeutics AG Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for treating BK viremia in kidney transplant patients.
Memo Therapeutics AG Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has finished enrolling patients in its Phase II clinical trial of potravitug, a BKV-neutralizing antibody, for kidney transplant recipients.